Vancomycin

Glycopeptide Antibiotic — Antibiotics

• Drug Class: Glycopeptide Antibiotic
• Category: Antibiotics
• Type: Small Molecule
• SMILES: C[C@H]1[C@H](O)[C@@H](O)[C@H](Oc2c3cc4cc2Oc2ccc(cc2Cl)[C@@H](O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H]2NC(=O)[C@@H](CC(=O)O)NC(=O)[C@H](NC(=O)C4=NO)c4cc(O)c(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)c(-c4cc3cc(Cl)c4O)c4O)C(=O)N2CCC[C@@H]2N)O[C@@H]1C

What is Vancomycin?

Vancomycin is a powerful glycopeptide antibiotic that plays a crucial role in combating serious bacterial infections. It is particularly vital for treating infections caused by Gram-positive bacteria, including strains that have developed resistance to other antibiotics, such as Methicillin-resistant Staphylococcus aureus (MRSA). Vancomycin is often reserved for more severe infections or when other treatments are not suitable due to its potency and potential for side effects. It is available as a generic medication, but also under brand names such as Vancocin. Understanding its properties, uses, and safety profile is essential for healthcare professionals and patients alike.

Mechanism of Action

Vancomycin exerts its bactericidal effect by interfering with bacterial cell wall synthesis. This complex process is essential for bacterial survival, providing structural integrity and protection against osmotic pressure. Vancomycin achieves this by binding with high affinity to the D-alanyl-D-alanine termini of the peptidoglycan precursor molecules. Specifically, it forms a hydrogen bond complex with the terminal D-Ala-D-Ala residues, thereby inhibiting the transglycosylation step, which is crucial for elongating the peptidoglycan chains. Furthermore, it inhibits the transpeptidation step, which cross-links these chains to form a rigid, stable cell wall. By disrupting these fundamental processes, Vancomycin weakens the bacterial cell wall, leading to cell lysis and death. Its specific binding to the D-Ala-D-Ala moiety is what makes it effective against many Gram-positive bacteria, as this structure is a common component of their cell walls.

Clinical Uses & Indications

Vancomycin is a cornerstone in the treatment of serious Gram-positive bacterial infections, especially those caused by resistant organisms. Its primary indications include:

• Treatment of serious infections caused by Gram-positive bacteria: This includes infections such as bacteremia, endocarditis, osteomyelitis, pneumonia, skin and soft tissue infections, and intra-abdominal infections.
• Treatment of infections caused by MRSA: Vancomycin is a first-line agent for infections caused by Methicillin-resistant Staphylococcus aureus (MRSA), a significant public health concern due to its resistance to many common antibiotics.
• Treatment of Clostridioides difficile infection (CDI): Oral vancomycin is highly effective in treating moderate to severe cases of C. difficile infection (formerly known as Clostridium difficile), an opportunistic infection often associated with antibiotic use that causes severe diarrhea and colitis.
• Prophylaxis against infective endocarditis: In certain high-risk patients undergoing specific dental or surgical procedures, vancomycin may be used prophylactically to prevent bacterial endocarditis.
• Treatment of other serious infections: It is also used for infections caused by other susceptible Gram-positive organisms, such as Streptococcus species (including penicillin-resistant strains), Enterococcus species (though resistance is increasing), and Corynebacterium species.

The FDA-approved uses of vancomycin are extensive and cover a broad range of severe Gram-positive bacterial infections. However, its use is guided by susceptibility testing and clinical judgment to ensure optimal efficacy and minimize the development of resistance.

Dosage & Administration

Vancomycin is typically administered intravenously (IV) for systemic infections, and orally for the treatment of C. difficile infection. The dosage and administration route are critical for achieving therapeutic levels while minimizing toxicity.

Intravenous (IV) Administration

For systemic infections, vancomycin is usually given as a continuous infusion or intermittent infusions over 60 minutes or longer. The dosage is carefully calculated based on the patient's weight (typically 15-20 mg/kg per dose), renal function, and the severity of the infection. Dosing intervals can range from 8 to 12 hours, or even longer in patients with significant renal impairment. Achieving and maintaining therapeutic trough concentrations (typically 10-20 mcg/mL) is crucial for efficacy and is monitored through regular blood tests. Rapid infusion can lead to adverse reactions, such as Red Man Syndrome.

Oral Administration

For C. difficile infection, vancomycin is administered orally. This route ensures high concentrations of the drug reach the colon, where the infection is localized. Doses typically range from 125 mg to 500 mg taken four times daily for 10-14 days. It is important to note that oral vancomycin is poorly absorbed from the gastrointestinal tract, which is why it is effective for local treatment of CDI but not for systemic infections.

Other Routes

In some specific situations, vancomycin can be administered via other routes:

• Intraperitoneal: Used for treating peritonitis in patients on continuous ambulatory peritoneal dialysis (CAPD).
• Intrathecal/Intraventricular: In rare cases, it may be administered directly into the cerebrospinal fluid for central nervous system infections, although this carries significant risks.

Dosage adjustments are essential, particularly in patients with impaired renal function, as vancomycin is primarily eliminated by the kidneys. Therapeutic drug monitoring is a standard practice to ensure safe and effective treatment.

Side Effects & Safety

While vancomycin is a life-saving medication, it is associated with several potential side effects and safety concerns that require careful monitoring.

Common Side Effects

The most common side effects associated with vancomycin include:

• Infusion-related reactions: Including Red Man Syndrome (RMS), characterized by flushing, erythema, pruritus, and sometimes hypotension, typically occurring during or shortly after rapid IV infusion. This is thought to be a histamine-mediated reaction and can often be managed by slowing the infusion rate.
• Phlebitis: Inflammation of the vein at the injection site.
• Nephrotoxicity: Kidney damage, which can manifest as elevated serum creatinine levels. The risk is increased with concurrent use of other nephrotoxic drugs or in patients with pre-existing renal impairment.
• Ototoxicity: Hearing loss or tinnitus (ringing in the ears). This is more common with high trough concentrations or prolonged therapy and can sometimes be irreversible.
• Hematologic changes: Such as neutropenia (low white blood cell count) or thrombocytopenia (low platelet count), which are usually reversible upon discontinuation of the drug.

Serious Side Effects and Contraindications

Serious adverse events, though less common, can occur:

• Anaphylaxis: Severe allergic reactions can occur, although they are rare.
• Clostridioides difficile-associated diarrhea: Ironically, while treating CDI, vancomycin can sometimes lead to or worsen other gastrointestinal issues.
• Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN): Rare but severe dermatological reactions.

Contraindications: Vancomycin is generally contraindicated in patients with known hypersensitivity to the drug. Caution is advised in patients with pre-existing renal impairment, hearing impairment, or those receiving other nephrotoxic or ototoxic agents. Pregnant and breastfeeding women should only use vancomycin if clearly needed and benefits outweigh risks.

Drug Interactions

Vancomycin can interact with several other medications, potentially increasing the risk of adverse effects or reducing its efficacy. Careful consideration of concurrent medications is necessary:

• Aminoglycosides: Concomitant use with aminoglycosides (e.g., gentamicin, tobramycin) significantly increases the risk of nephrotoxicity and ototoxicity. If used together, close monitoring of renal function and drug levels is essential.
• Diuretics: Loop diuretics (e.g., furosemide) can potentiate the nephrotoxic and ototoxic effects of vancomycin.
• Anesthetics: Concurrent use with anesthetics has been associated with increased risk of neuromuscular blockade and histamine-mediated reactions (like Red Man Syndrome). Anesthesiologists should be informed of vancomycin administration.
• Other Nephrotoxic Drugs: Medications known to cause kidney damage, such as amphotericin B, cisplatin, and NSAIDs, can enhance vancomycin's nephrotoxic potential.
• Anticoagulants: Vancomycin may potentially increase the effect of warfarin, leading to an increased risk of bleeding, although this interaction is not well-established and requires monitoring.

It is imperative for healthcare providers to review a patient's complete medication list before initiating vancomycin therapy to identify and manage potential drug interactions proactively.

Molecular Properties

Vancomycin is a complex molecule with a unique structure that dictates its pharmacological activity. Its detailed molecular properties are:

Molecular Formula:	C66H75Cl2N9O24
Molecular Weight:	1449.25 g/mol
Structure Description:	Vancomycin is a tricyclic glycopeptide antibiotic. Its structure consists of a heptapeptide backbone that is cross-linked to form a rigid structure. It features several unusual amino acids and a disaccharide moiety (vancosamine and glucose). The molecule's complex three-dimensional structure is crucial for its binding to the D-Ala-D-Ala target in bacterial cell wall precursors. The presence of chlorine atoms and multiple hydroxyl groups contributes to its polarity and solubility.
SMILES Notation:	C[C@H]1[C@H](O)[C@@H](O)[C@H](Oc2c3cc4cc2Oc2ccc(cc2Cl)[C@@H](O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H]2NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](NC(=O)C4=NO)c4cc(O)c(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)c(-c4cc3cc(Cl)c4O)c4O)C(=O)N2CCC[C@@H]2N)O[C@@H]1C

The intricate structure, represented by the SMILES notation C[C@H]1[C@H](O)[C@@H](O)[C@H](Oc2c3cc4cc2Oc2ccc(cc2Cl)[C@@H](O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H]2NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](NC(=O)C4=NO)c4cc(O)c(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)c(-c4cc3cc(Cl)c4O)c4O)C(=O)N2CCC[C@@H]2N)O[C@@H]1C, is key to its specific mechanism of action and its efficacy against Gram-positive bacteria.

Analyze Vancomycin with MolForge

Understanding the intricate molecular details of vancomycin, from its complex structure and properties to its mechanism of action and potential interactions, is vital for drug discovery and development. MolForge's AI-powered platform offers advanced tools to explore molecules like vancomycin in unprecedented depth. You can analyze its structure, predict its properties, investigate potential binding sites, and explore its behavior in various biological contexts. Harness the power of AI to accelerate your research. Explore vancomycin and countless other molecules in our interactive dashboard: MolForge Dashboard.